Zobrazeno 1 - 10
of 68
pro vyhledávání: '"Mason KJ"'
Autor:
Mason, KJ, Jordan, KP, Achana, FA, Bailey, J, Chen, Y, Frisher, M, Huntley, AL, Mallen, CD, Mamas, MA, Png, ME, Tatton, S, White, S, Edwards, JJ
Publikováno v:
Rheumatology. 61
Background/Aims There is some evidence of an increased risk of cardiovascular disease in patients with painful musculoskeletal conditions, but it is unclear if musculoskeletal pain also worsens its prognosis. The aim was to determine whether patients
Autor:
Mason, KJ, Jordan, K, Achana, F, Bailey, J, Chen, Y, Frisher, M, Heron, N, Huntely, A, Mallen, C, Mamas, M, Marshall, M, Png, ME, Tatton, S, White, S, Edwards, JJ
Publikováno v:
SAPC North 2021
Background: There is evidence that painful musculoskeletal conditions are associated with increased risk of cardiovascular disease, but less is known about whether this impacts on prognosis of cardiovascular disease. The aim was to determine whether
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=core_ac_uk__::aaf4735513d321fd319a42c21588d144
https://eprints.keele.ac.uk/10193/1/2021_09_Final_SAPCNorth_MSKCOM_CVD.docx
https://eprints.keele.ac.uk/10193/1/2021_09_Final_SAPCNorth_MSKCOM_CVD.docx
Autor:
Yiu, ZZN, Mason, KJ, Barker, JNWN, Hampton, PJ, McElhone, K, Smith, CH, Warren, RB, Griffiths, CEM, Lunt, M, Burden, AD, Study Group, BADBIR
Publikováno v:
The British Journal of Dermatology
Yiu, Z Z N, Mason, K J, Barker, J N W N, Hampton, P J, McElhone, K, Smith, C H, Warren, R B, Griffiths, C E M, Lunt, M & Burden, A D 2019, ' A standardization approach to compare treatment safety and effectiveness outcomes between clinical trials and real-world populations in psoriasis ', British Journal of Dermatology . https://doi.org/10.1111/bjd.17849
Yiu, Z Z N, Mason, K J, Barker, J N W N, Hampton, P J, McElhone, K, Smith, C H, Warren, R B, Griffiths, C E M, Lunt, M & Burden, A D 2019, ' A standardization approach to compare treatment safety and effectiveness outcomes between clinical trials and real-world populations in psoriasis ', British Journal of Dermatology . https://doi.org/10.1111/bjd.17849
Summary Background Patients recruited in randomized controlled trials (RCTs) for biologic therapies in psoriasis are not fully representative of the real‐world psoriasis population. Objectives Firstly, to investigate whether patient characteristics
Autor:
Rungapiromnan, W, Mason, KJ, Lunt, M, McElhone, K, Rutter, MK, Warren, RB, Griffiths, CEM, Ashcroft, DM, Grp, BADBIRS
Background\ud The cardiovascular safety profile of biologic therapies used for psoriasis is unclear.\ud \ud Objectives\ud To compare the risk of major cardiovascular events (CVE s; acute coronary syndrome, unstable angina, myocardial infarction and s
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=core_ac_uk__::749b488351b8d274b4c281508ed51993
https://eprints.keele.ac.uk/8508/1/jdv.16018.pdf
https://eprints.keele.ac.uk/8508/1/jdv.16018.pdf
Autor:
Warren, RB, Marsden, A, Tomenson, B, Mason, KJ, Soliman, MM, Burden, AD, Reynolds, NJ, Stocken, D, Emsley, R, Griffiths, CEM, Smith, C, PSORT Consortium and on behalf of the BADBIR Study Group
BACKGROUND: Biologic therapies have revolutionized the treatment of moderate-to-severe psoriasis. However, for reasons largely unknown, many patients do not respond or lose response to these drugs. OBJECTIVES: To evaluate demographic, social and clin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=core_ac_uk__::a9267052c77be2f95930a90b6907097e
https://researchonline.lshtm.ac.uk/id/eprint/4653882/1/Warren-etal-Identifting-demographic-social-and-clinical-predictors-of-biologic-therapy-effectiveness.pdf
https://researchonline.lshtm.ac.uk/id/eprint/4653882/1/Warren-etal-Identifting-demographic-social-and-clinical-predictors-of-biologic-therapy-effectiveness.pdf
Autor:
Yiu, ZZN, Sorbe, C, Lunt, M, Rustenbach, SJ, Kühl, L, Augustin, M, Mason, KJ, Ashcroft, DM, Griffiths, CEM, Warren, RB, BADBIR Study Group
BACKGROUND: Patients with psoriasis are often concerned about the risk of serious infection associated with systemic psoriasis treatments. OBJECTIVES: To develop and externally validate a prediction model for serious infection in patients with psoria
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=core_ac_uk__::33c67bcc2c7e74c34ab1ee371603eb5b
Autor:
Warren, RB, Marsden, A, Tomenson, B, Mason, KJ, Soliman, MM, Burden, AD, Reynolds, NJ, Stocken, D, Emsley, R, Griffiths, CEM, Smith, C, Consortium, PSORT, Study Group, BADBIR
BACKGROUND: Biologic therapies have revolutionized the treatment of moderate-to-severe psoriasis. However, for reasons largely unknown, many patients do not respond or lose response to these drugs. OBJECTIVES: To evaluate demographic, social and clin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=core_ac_uk__::3ea189ce059f099835a64fc4667a8b00
Autor:
Iskandar, IYK, Warren, RB, Lunt, M, Mason, KJ, Evans, I, McElhone, K, Smith, CH, Reynolds, NJ, Ashcroft, DM, Griffiths, CEM, Study Group, BADBIR
Publikováno v:
The Journal of Investigative Dermatology
Iskandar, I Y K, Warren, R B, Lunt, M, Mason, K J, Evans, I, McElhone, K, Smith, C H, Reynolds, N J, Ashcroft, D M, Griffiths, C E M & BADBIR Study Group 2018, ' Differential Drug Survival of Second-Line Biologic Therapies In Patients with Psoriasis : Observational Cohort Study from the British Association of Dermatologists Biologic Interventions Register (BADBIR) ', The Journal of Investigative Dermatology, vol. 138, pp. 775-784 . https://doi.org/10.1016/j.jid.2017.09.044
Iskandar, I Y K, Warren, R B, Lunt, M, Mason, K J, Evans, I, McElhone, K, Smith, C H, Reynolds, N J, Ashcroft, D M, Griffiths, C E M & BADBIR Study Group 2018, ' Differential Drug Survival of Second-Line Biologic Therapies In Patients with Psoriasis : Observational Cohort Study from the British Association of Dermatologists Biologic Interventions Register (BADBIR) ', The Journal of Investigative Dermatology, vol. 138, pp. 775-784 . https://doi.org/10.1016/j.jid.2017.09.044
Little is known about the drug survival of second-line biologic therapies for psoriasis in routine clinical practice. We assessed drug survival of second-line biologic therapies and estimated the risk of recurrent discontinuation due to adverse event
Autor:
Mason, KJ, Evans, I, McElhone, K, Lunt, M, Hussain, S, Kirby, B, Burden, A, Reynolds, NJ, Griffiths, CE
Publikováno v:
In Value in Health November 2016 19(7):A573-A573
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.